379 results on '"Vanhoorelbeke K"'
Search Results
2. OC 26.4 A Microfluidic Approach in TTP Highlights the Need to Normalise ADAMTS13 Activity Levels in Clinical Remission
3. PB1220 DNase-1 Overcomes Thrombolytic rT-PA Resistance of Platelet-Rich Ischemic Stroke Thrombi
4. OC 26.5 Regulation of VWF Cleavage is Mediated by Coupling ADAMTS13 Dand C- Domain Binding Sites
5. OC 42.3 Immune-Mediated TTP Patients in Remission with Recovered ADAMTS13 Activity but an Open ADAMTS13 Conformation are at Risk for Earlier ADAMTS13 Relapse
6. OC 26.2 Exploring Structural Dynamics in the ADAMTS13 CUB Domains Upon Antibody-Mediated ADAMTS13 Activation
7. PB0873 Small-Molecule Cyclophilin Inhibitors Potently Reduce Platelet Procoagulant Activity
8. High and long‐term von Willebrand factor expression after Sleeping Beauty transposon‐mediated gene therapy in a mouse model of severe von Willebrand disease
9. An open conformation of ADAMTS‐13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura
10. Platelet rescue by macrophage depletion in obese ADAMTS‐13‐deficient mice at risk of thrombotic thrombocytopenic purpura
11. Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice
12. ADAMTS‐13 glycans and conformation‐dependent activity
13. The Von Willebrand factor multimer ratio and inflammatory markers in autoimmune thrombotic thrombocytopenic purpura
14. Linker regions and flexibility around the metalloprotease domain account for conformational activation of ADAMTS‐13
15. The novel ADAMTS13‐p.D187H mutation impairs ADAMTS13 activity and secretion and contributes to thrombotic thrombocytopenic purpura in mice
16. Animal models for thrombotic thrombocytopenic purpura
17. The distal carboxyterminal domains of murine ADAMTS13 influence proteolysis of platelet‐decorated VWF strings in vivo
18. Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura
19. Multi‐step binding of ADAMTS‐13 to von Willebrand factor
20. Identification of a VWF peptide antagonist that blocks platelet adhesion under high shear conditions by selectively inhibiting the VWF‐collagen interaction
21. Evolutionary variation in the allosteric properties of ADAMTS13: OR365
22. Recombinant ADAMTS13 as an effective therapy for acquired thrombotic thrombocytopenic purpura in rats: OR151
23. Endogenous plasmin levels control the development of acute episodes of thrombotic thrombocytopenic purpura in mice: OR153
24. Long-term gene therapy for thrombotic thrombocytopenic purpura using the ‘Sleeping Beauty’ transposon system: OR155
25. Long-term expression of von willebrand factor VIA sleeping beauty sandwich transposon-mediated gene therapy: OR087
26. Riboflavin and amotosalen photochemical treatments of platelet concentrates reduce thrombus formation kinetics in vitro
27. The GPIbα intracellular tail - role in transducing VWF- and Collagen/GPVI-mediated signaling
28. Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS‐13)
29. Allosteric activation of ADAMTS13 involves conformational changes induced by its substrate von Willebrand factor: VWF02
30. Crystal structure of ADAMTS13 CUB domains reveals their role in global latency
31. Platelet adhesion to dimeric β2‐glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibα and apolipoprotein E receptor 2′
32. FRET rather than CBA reflects ADAMTS13 proteolytic activity in thrombotic thrombocytopenic purpura patients with discordant measurements: PB 3.33–4
33. A new heterozygous mutation in the metalloprotease domain of ADAMTS13 in a patient with thrombotic thrombocytopenic purpura: PB 2.73–2
34. Establishment of conditions for in vitro and in vivo production of genetically modified human megakaryocytes and platelets: PB 1.29–2
35. The role of platelet von Willebrand factor in mice: OC 65.4
36. The newly identified platelet receptor DCBLD2 is involved in platelet activation and thrombus formation: OC 60.6
37. ADAMTS13 is autoinhibited by distal thrombospondin-1 (T) or CUB domains and is activated allosterically by VWF or antibodies against ADAMTS13 domain T8: OC 15.3
38. ADAMTS13 meets von Willebrand factor strings: a single molecule approach: OC 15.1
39. In vivo von Willebrand factor size heterogeneity in spite of the clinical deficiency of ADAMTS-13
40. Inhibition of adamts13: a novel therapy to treat mechanical circulatory support-induced acquired von willebrand syndrome
41. Active platelet-binding conformation of plasma von Willebrand factor in young women with acute myocardial infarction
42. Deficiency of von willebrand factor protects mice from ischemic stroke: OC-WE-040
43. Unproductive binding of ADAMTS13 to von willebrand factor: AS-MO-014
44. Activation of platelet integrin α2β1: 67
45. ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences
46. Development of Monoclonal Antibodies that Inhibit Platelet Adhesion or Aggregation as Potential Anti-Thrombotic Drugs
47. The von Willebrand factor self-association is modulated by a multiple domain interaction
48. Illustrated State-of-the-Art Capsules of the ISTH 2019 Congress in Melbourne, Australia
49. Platelet antigens and their function
50. Inhibition of Platelet Adhesion to Collagen as a New Target for Antithrombotic Drugs
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.